Recombinant Rat LGALS9 Protein
Cat.No. : | LGALS9-3392R |
Product Overview : | Recombinant Rat LGALS9 full length or partial length protein was expressed. |
- Specification
- Gene Information
- Related Products
Source : | Mammalian Cells |
Species : | Rat |
Tag : | His |
Form : | Liquid or lyophilized powder |
Endotoxin : | < 1.0 EU per μg of the protein as determined by the LAL method. |
Purity : | >80% |
Notes : | This item requires custom production and lead time is between 5-9 weeks. We can custom produce according to your specifications. |
Storage : | Store it at +4 ºC for short term. For long term storage, store it at -20 ºC~-80 ºC. |
Storage Buffer : | PBS buffer |
Gene Name : | Lgals9 lectin, galactoside-binding, soluble, 9 [ Rattus norvegicus ] |
Official Symbol : | LGALS9 |
Gene ID : | 25476 |
mRNA Refseq : | NM_012977.1 |
Protein Refseq : | NP_037109.1 |
MIM : | |
UniProt ID : | P97840 |
Products Types
◆ Recombinant Protein | ||
Lgals9-1314M | Recombinant Mouse Lgals9 Protein, MYC/DDK-tagged | +Inquiry |
Lgals9-435M | Recombinant Mouse Lgals9 Protein(Met1-Thr322), GST-tagged | +Inquiry |
LGALS9-660H | Recombinant Human LGALS9 Protein | +Inquiry |
LGALS9-2145H | Recombinant Human LGALS9 Protein (1-323 aa), His-tagged | +Inquiry |
LGALS9-3048R | Recombinant Rat LGALS9 Protein, His (Fc)-Avi-tagged | +Inquiry |
◆ Lysates | ||
LGALS9-4761HCL | Recombinant Human LGALS9 293 Cell Lysate | +Inquiry |
Related Gene
For Research Use Only. Not intended for any clinical use. No products from Creative BioMart may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative BioMart.
Inquiry
- Q&As
- Reviews
Q&As (5)
Ask a questionYes, there are clinical trials investigating the use of LGALS9-based therapies in cancer treatment, with a focus on immunotherapy approaches.
There is emerging research on the potential use of LGALS9 in modulating immune responses to infectious diseases, particularly in the context of viral infections.
Challenges include optimizing the delivery and dosing of LGALS9-based therapies and addressing potential adverse effects on immune homeostasis.
LGALS9 is being investigated for its potential to induce immune tolerance and mitigate transplant rejection in preclinical studies.
LGALS9 has been found to promote the activation and proliferation of cytotoxic T lymphocytes, which are key players in the immune response against cancer cells.
Customer Reviews (3)
Write a reviewIt has demonstrated outstanding performance in ELISA, providing reliable and precise results.
It has been invaluable in protein electron microscopy structure analysis, facilitating detailed investigations and yielding valuable insights.
I highly recommend the LGALS9 protein for various experimental applications.
Ask a Question for All LGALS9 Products
Required fields are marked with *
My Review for All LGALS9 Products
Required fields are marked with *
Inquiry Basket